Investors in early stage in vitro diagnostic technologies
ABOUT
Who We Are:
CS Ventures is the corporate venture arm of Canterbury Scientific Ltd., a privately held, global leader in the development, manufacturing, and supply of in vitro diagnostic (IVD) controls and calibrators.
We were established in 2019 to search globally for investment opportunities in novel, early-stage, IVD technologies that enable diversification beyond the haemoglobin products for which Canterbury Scientific is so well known.
Our non-confidential investments include Aptatek Biosciences (USA) and MiMARK (Spain).
What We Are Looking For:
CS Ventures searches exclusively for innovative in vitro diagnostic technologies that are strategically aligned with Canterbury Scientific’s manufacturing specialties. With flexibility in investment structure and stage, we combine capital with unparalleled industry knowledge to drive the development and commercialisation of transformative diagnostics.
If you have any questions regarding our interests or want to share your technology, please use the form at the bottom of this page.
Type of Technology: Novel in vitro diagnostic technologies that incorporate one or more of the following:
-
Proprietary biomarkers
-
Lateral flow applications
-
Non-standard biological fluid controls and/or calibrators
-
Scalable protein purification
Intellectual Property: Technology must have robust and protectable IP or the potential for IP.
Application Area: Any indication where there is an unmet need, except for diabetes mellitus.
Stage of Development: Pre-market - at or beyond the human proof of concept and prototype stage (TRL 4+).
Deal Structure: Flexible - offering a broad range of investment and licensing models, tailored to your technology’s needs.
Geographical Scope: Jurisdiction agnostic - we are interested in technologies from all around the world.
What We Offer:
CS Ventures is a strategic partner to our portfolio companies. We are actively involved, combining Canterbury Scientific’s deep scientific, quality, and regulatory industry expertise with the scientific ingenuity of researchers and founders to maximise success.
We utilise Canterbury Scientific’s manufacturing facilities, including state-of-the-art chromatography, lyophilisation, centrifugation, and filling/capping systems.
​
Proven Expertise: Decades of experience in designing and manufacturing high-quality biological controls.
Regulatory Proficiency, including:
-
EU 2017/746 IVDR Certification & 98/79/EC IVDD CE-Mark
-
US FDA 21 CFR part 820 & 510(k) Premarket Approvals
Quality Excellence: Experience building robust quality systems:
-
ISO 13485:2016
-
cGMP
Global Industry Network: Extensive connections across the IVD landscape.
OUR TEAM
Dr Robert Feldman
CS Ventures Head
Robert combines over 30 years of medical, academic, and business expertise in the biotechnology and medical technology industries. A qualified medical practitioner, he studied at three of the world’s top ten universities, earning his medical degree in London and a PhD in the Netherlands. His career includes roles at Harvard Medical School and Imperial College London, as well as founding multiple biotechnology companies in the UK.
Robert has led European operations for Paramount Biosciences, LLC, and served as Entrepreneur in Residence at Imperial Innovations, London. In 2010, he moved to New Zealand to become Executive Director at Pacific Channel, a leading venture investment firm.
He possesses a breadth of medical and research expertise encompassing therapeutics, devices, diagnostics, and functional health preparations, with a proven ability to commercialize early-stage technologies. Robert’s global experience includes successful business development and licensing deals across Europe, the USA, Australia, Russia, South Korea, and New Zealand. With a nuanced understanding of the challenges in bringing innovations to market, he excels at transforming early-stage technologies into impactful solutions that advance human health.
Helen Haywood
Technology Analyst
Helen, a Biomedical Science graduate with hands-on experience in start-ups and a proactive approach to industry engagement, brings a robust foundation in laboratory work and practical insights to this role.
Her passion for bridging the gap between academic research and industry applications aligns with our mission to help the development of impactful technologies that enhance healthcare delivery.
With a background in science communication, innovation, and engagement, Helen is equipped with the essential skills to advance meaningful scientific solutions, ensuring that our approach is both scientifically sound and socially relevant.
CONTACT
CS Ventures
If you would like to get in touch or have an in vitro diagnostic opportunity that you’d like to discuss, please fill out the following form. We look forward to hearing from you!
